Brain scans for diagnosing and tracking Alzheimer's disease
Part of Brain & nervous system, Mental health clinical trials.
This study uses special PET brain scans to look at proteins linked to Alzheimer's disease, which may help diagnose it and track how it changes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- For healthy volunteers: weigh at least 50 kg if male, 45 kg if female, with a BMI between 19 and 28.
- You have a clinical diagnosis of Alzheimer's disease or mild cognitive impairment, or you are a healthy volunteer.
- You have no major illnesses, including heart disease, cancer, or blood disorders.
- You are not pregnant, breastfeeding, or allergic to contrast agents.
- You have no history of head trauma, brain surgery, or neurological disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses artificial intelligence to create a simulated FDG PET brain scan from an amyloid PET scan. This could help doctors monitor Alzheimer's disease without needing an extra scan, making diagnosis and tracking easier.
This trial uses special PET scans to see amyloid and tau proteins in the brain, which are linked to Alzheimer's. It aims to find these changes early, in people with mild memory problems or early-stage Alzheimer's.
This trial uses a new type of PET scan to look for specific proteins in the brain that are linked to Alzheimer's disease. It will help doctors see how these proteins relate to cognitive decline and compare scans from people with normal thinking to those with memory problems.
This study uses a special PET brain scan to look at two types of brain immune cells in people with Alzheimer’s. It may help researchers better understand Alzheimer’s and how these cells change over time.
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
Hear when a new Cognitive Dysfunction, Cognitive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.